Effects of probucol on hepatic tumor necrosis factor-α, interleukin-6 and adiponectin receptor-2 expression in diabetic rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 6, 2009, Pages 1058-1063

  Zhang, Xia ^a   Li, Zhongzhuan ^a   Liu, Dongfang ^a   Xu, Xin ^a   Shen, Wei ^a   Mei, Zhechuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

High fat diet; Insulin resistance; Non alcoholic fatty liver disease; Oxidative stress; Probucol

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 2; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN; INTERLEUKIN 6; MESSENGER RNA; PROBUCOL; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; GENE EXPRESSION; HOMEOSTASIS; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER HISTOLOGY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; INTERLEUKIN-6; MALE; PROBUCOL; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, ADIPONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66549096911     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05719.x     Document Type: Article

References (35)

1. Angelico F, Ben M, Conti R et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003 18 : 588 94.
2. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 : 917 23.
3. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003 26 : 2442 50.
4. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes. Metab. 2006 8 : 264 80.
5. Matsushita K, Yatsuya H, Tamakoshi K et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler. Thromb. Vasc. Biol. 2006 26 : 871 6.
6. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 : 762 9.
7. Tsuchida A, Yamauchi T, Ito Y et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem. 2004 279 : 30817 22.
8. Endo K, Miyashita Y, Sasaki H et al. Probucol and atorvastatin decrease urinary 8-hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia. J. Atheroscler. Thromb. 2006 13 : 68 75.
9. Endo K, Miyashita Y, Sasaki H et al. Probucol delays progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 2006 71 : 156 63.
10. Merat S, Aduli M, Kazemi R et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig. Dis. Sci. 2008 53 : 2246 50.
11. Yasunari K, Kohno M, Kano H, Yokokura K, Minami M, Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 1999 99 : 1370 8.
12. Ikeda T, Sakurai J, Nakayama D et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am. J. Hypertens. 2004 17 : 502 6.
13. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 21.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
15. Esposito K, Ciotola M, Sasso FC et al. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. Nutr. Metab. Cardiovasc. Dis. 2007 17 : 274 9.
16. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006 40 : S17 S29.
17. Itoh S, Umemoto S, Hiromoto M et al. Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation 2002 105 : 2288 95.
18. Merat S, Malekzadeh R, Sohrabi MR. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J. Hepatol. 2003 38 : 414 8.
19. Lacquemant C, Vasseur F, Lepretre F, Froguel P. Adipocytokins, obesity and development of type 2 diabetes. Med. Sci. (Paris) 2003 19 : 809 17.
20. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997 389 : 610 4.
21. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996 271 : 665 8.
22. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001 48 : 206 11.
23. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 : 1158 63.
24. Satapathy SK, Garg S, Chauhan R et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004 99 : 1946 52.
25. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005 11 : 183 90.
26. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008 103 : 1372 9.
27. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2002 96 : 1723 32.
28. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001 7 : 941 6.
29. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003 112 : 91 100. (Pubitemid 38056380)
30. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 : 117 21.
31. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001 96 : 519 25.
32. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003 38 : 1008 17.
33. Seo YS, Kim JH, Jo NY et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroenterol. Hepatol. 2008 23 : 102 9.
34. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003 52 : 1655 63.
35. Liu GX, Ou DM, Liu JH, Huang HL, Liao DF. Probucol inhibits lipid peroxidation of macrophage and affects its secretory properties. Acta Pharmacol. Sin. 2000 21 : 637 40.